Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated (VRTX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · VRTX · as of Mar 31, 2025
Ownership Breakdown
1,680
Institutional Holders
▲ 45 vs Q4
$116.42B
Total Inst. Value
▲ $21.26B vs Q4
253.81M
Shares Outstanding
freeFloat 99.69%
240.11M
13F Shares Held
▲ 3.70M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
VRTX largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
CAPITAL WORLD INVESTORS pharmaceutical preparations | 28.53M | 11.11% | 11.11% | $13.83T | May 12, 2025 | ▲ 207.6K |
VANGUARD GROUP INC pharmaceutical preparations | 23.49M | 9.14% | 9.14% | $11.39T | May 9, 2025 | ▲ 232.9K |
BLACKROCK, INC. pharmaceutical preparations | 21.78M | 8.48% | 8.48% | $10.56T | May 2, 2025 | ▼ 42.5K |
CAPITAL RESEARCH GLOBAL INVESTORS pharmaceutical preparations | 14.54M | 5.66% | 5.66% | $7.05T | May 12, 2025 | ▲ 4.11M |
STATE STREET CORP pharmaceutical preparations | 11.79M | 4.59% | 4.59% | $5.72T | May 15, 2025 | ▼ 190.7K |
JPMORGAN CHASE & CO pharmaceutical preparations | 7.76M | 3.02% | 3.02% | $3.76T | May 12, 2025 | ▲ 1.44M |
FMR LLC pharmaceutical preparations | 7.73M | 3.01% | 3.01% | $3.75T | May 12, 2025 | ▼ 1.49M |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 5.76M | 2.24% | 2.24% | $2.78T | May 13, 2025 | ▲ 113.5K |
WELLINGTON MANAGEMENT GROUP LLP pharmaceutical preparations | 5.45M | 2.12% | 2.12% | $2.64T | May 13, 2025 | ▼ 461.3K |
JENNISON ASSOCIATES LLC pharmaceutical preparations | 5.06M | 1.97% | 1.97% | $2.45T | May 5, 2025 | ▲ 744.7K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
22
Increased
+10.47M shares1
New Positions
first time holders27
Decreased
−4.49M shares0
Sold Out
fully exitedNet shares change (top 50)
+5.98M
+10.47M / −4.49M
Net new holders
-4
1 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
VRTX insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
19
Buy transactions
8
Sell transactions
2.38
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Bozic Carmen EVP and CMO | May 29, 2026 | Sale | 1,974 | $450.00 | $888.3K | 22.8K | Form 4 ↗ |
Bunnage Mark E. EVP, Chief Scientific Officer | May 15, 2026 | Sale | 33 | $453.45 | $15.0K | 7.3K | Form 4 ↗ |
Bozic Carmen EVP and CMO | May 15, 2026 | Sale | 1,354 | $453.45 | $614.0K | 24.7K | Form 4 ↗ |
Bozic Carmen EVP and CMO | May 12, 2026 | Sale | 6,988 | $450.00 | $3.14M | 26.1K | Form 4 ↗ |
Upadhyay Suketu director | May 1, 2026 | Award | 796 | — | — | 3.6K | Form 4 ↗ |
Upadhyay Suketu director | May 1, 2026 | Award | 2,866 | $424.45 | $1.22M | 2.9K | Form 4 ↗ |
Upadhyay Suketu director | May 1, 2026 | D-Return | 796 | — | — | 1.6K | Form 4 ↗ |
Thornberry Nancy director | May 1, 2026 | Award | 472 | — | — | 2.5K | Form 4 ↗ |
Thornberry Nancy director | May 1, 2026 | D-Return | 398 | — | — | 2.1K | Form 4 ↗ |
Thornberry Nancy director | May 1, 2026 | Award | 1,433 | $424.45 | $608.2K | 1.4K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Vertex Pharmaceuticals Incorporated (VRTX) is primarily owned by institutional investors, who hold approximately 94.6% of total shares outstanding. Company insiders own approximately 0.31%, while retail and public investors account for the remaining 5.09%.
The largest institutional shareholder of Vertex Pharmaceuticals Incorporated is CAPITAL WORLD INVESTORS, holding approximately 28.53 million shares — equal to 11.11% of outstanding shares — as of March 31, 2025.
A total of 1,680 institutional investors currently hold VRTX stock, with a combined institutional value of approximately $116.42 billion as of the most recent 13F filing period.
Frequently asked questions
VRTX ownershipVertex Pharmaceuticals Incorporated (VRTX) is primarily owned by institutional investors, who hold approximately 94.6% of shares. The largest shareholder is CAPITAL WORLD INVESTORS with a 11.11% stake. Company insiders hold 0.31%. Data sourced from SEC Form 13F as of March 31, 2025.